{"disease":{"id":"indeterminate-lesions","name":"indeterminate lesions"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06007690","title":"A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Aura Biosciences","has_results":false},{"nct_id":"NCT07338968","title":"A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Aura Biosciences","has_results":false},{"nct_id":"NCT07421739","title":"Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects","phase":"","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Aura Biosciences","has_results":false},{"nct_id":"NCT05266430","title":"Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)","phase":"","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Aura Biosciences","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}